LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Corrigendum: Glucose-Regulated Protein 78 Signaling Regulates Hypoxia-Induced Epithelial-Mesenchymal Transition in A549 Cells.

    Sun, Ling-Ling / Chen, Chang-Ming / Zhang, Jue / Wang, Jing / Yang, Cai-Zhi / Lin, Li-Zhu

    Frontiers in oncology

    2020  Volume 10, Page(s) 615415

    Abstract: This corrects the article .]. ...

    Abstract [This corrects the article .].
    Language English
    Publishing date 2020-12-15
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2020.615415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway.

    Yang, Cai-Zhi / Guo, Wei / Wang, Yi-Fan / Hu, Lei-Hao / Wang, Jing / Luo, Jia-Min / Yao, Xiao-Hui / Liu, Shan / Tao, Lan-Ting / Sun, Ling-Ling / Lin, Li-Zhu

    Journal of ethnopharmacology

    2023  Volume 314, Page(s) 116566

    Abstract: Ethnopharmacological relevance: The Chinese herbal prescription Yi-Fei San-Jie pill (YFSJ) has been used for adjuvant treatment in patients with lung cancer for a long time.: Aim of the study: Reports have indicated that the combination of gefitinib ( ...

    Abstract Ethnopharmacological relevance: The Chinese herbal prescription Yi-Fei San-Jie pill (YFSJ) has been used for adjuvant treatment in patients with lung cancer for a long time.
    Aim of the study: Reports have indicated that the combination of gefitinib (Gef) with YFSJ inhibits the proliferation of EGFR-TKI-resistant cell lines by enhancing cellular apoptosis and autophagy in non-small cell lung cancer (NSCLC). However, the molecular mechanisms underlying the effect of YFSJ on EGFR-TKI resistance and related metabolic pathways remain to be explored.
    Materials and methods: In our report, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), metabolomics, network pharmacology, bioinformatics, and biological analysis methods were used to investigate the mechanism.
    Results: The UPLC-MS/MS data identified 42 active compounds of YFSJ extracts. YFSJ extracts can enhance the antitumor efficacy of Gef without hepatic and renal toxicity in vivo. The analysis of the metabolomics pathway enrichment revealed that YFSJ mainly affected the tyrosine metabolism pathway in rat models. Moreover, YFSJ has been shown to reverse Gef resistance and improve the effects of Gef on the cellular viability, migration capacity, and cell cycle arrest of NSCLC cell lines with EGFR mutations. The results of network pharmacology and molecular docking analyses revealed that tyrosine metabolism-related active compounds of YFSJ affect EGFR-TKIs resistance in NSCLC by targeting cell cycle and the MET/EGFR signaling pathway; these findings were validated by western blotting and immunohistochemistry.
    Conclusions: YFSJ inhibits NSCLC by inducing cell cycle arrest in the G1/S phase to suppress tumor growth, cell viability, and cell migration through synergistic effects with Gef via the tyrosine metabolic pathway and the EGFR/MET signaling pathway. To summarize, the findings of the current study indicate that YFSJ is a prospective complementary treatment for Gef-resistant NSCLC.
    MeSH term(s) Rats ; Animals ; Carcinoma, Non-Small-Cell Lung/pathology ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Lung Neoplasms/pathology ; Molecular Docking Simulation ; Chromatography, Liquid ; Prospective Studies ; ErbB Receptors/metabolism ; Drug Resistance, Neoplasm ; Tandem Mass Spectrometry ; Signal Transduction ; Cell Cycle ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Cell Proliferation
    Chemical Substances Gefitinib (S65743JHBS) ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2023-05-09
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2023.116566
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Glucose-Regulated Protein 78 Signaling Regulates Hypoxia-Induced Epithelial-Mesenchymal Transition in A549 Cells.

    Sun, Ling-Ling / Chen, Chang-Ming / Zhang, Jue / Wang, Jing / Yang, Cai-Zhi / Lin, Li-Zhu

    Frontiers in oncology

    2019  Volume 9, Page(s) 137

    Abstract: Objective: ...

    Abstract Objective:
    Language English
    Publishing date 2019-03-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2019.00137
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer.

    Yang, Cai-Zhi / Yang, Ting / Liu, Xue-Ting / He, Can-Feng / Guo, Wei / Liu, Shan / Yao, Xiao-Hui / Xiao, Xi / Zeng, Wei-Ran / Lin, Li-Zhu / Huang, Zhong-Yu

    Frontiers in genetics

    2022  Volume 13, Page(s) 982030

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2022-09-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606823-0
    ISSN 1664-8021
    ISSN 1664-8021
    DOI 10.3389/fgene.2022.982030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials.

    Chen, Zhi-Qiang / Li, Ze-Yun / Yang, Cai-Zhi / Lin, Rui-Ting / Lin, Li-Zhu / Sun, Ling-Ling

    Complementary therapies in medicine

    2019  Volume 47, Page(s) 102167

    Abstract: Objective: To systematically review and evaluate the effectiveness of Chinese herbal medicine (CHM) therapy for epidermal growth factor receptor inhibitor (EGFRI)-induced skin rash in patients with malignancy.: Methods: The electronic databases of ... ...

    Abstract Objective: To systematically review and evaluate the effectiveness of Chinese herbal medicine (CHM) therapy for epidermal growth factor receptor inhibitor (EGFRI)-induced skin rash in patients with malignancy.
    Methods: The electronic databases of Medline, PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, VIP Chinese Sci-tech Journal, Wan Fang, and Chinese Biomedicine were searched from their inception to 31 st September 2018. Randomized controlled trials (RCTs) investigating the effectiveness of CHM in improving EGFRI-induced skin rash were analyzed by Review Manager 5.3.
    Results: Twenty-three eligible RCTs with 1392 participants were identified and divided into four subgroups according to different treatment rules of Traditional Chinese Medicine (TCM) and different controls. CHM (dispel wind, clear heat, and eliminate dampness), the representative formula Xiao Feng San, is more effective than western medicine in improving and curing skin rash(RR,95%CI: 1.46,1.26-1.70 and 1.65,1.24-2.20); CHM (nourish yin, clear heat, and remove toxin for eliminating blood stasis), the representative formula Yang Fei Xiao Zhen Tang, is more effective than western medicine in improving skin rash(RR,95%CI: 1.45,1.10-1.92). CHM (clear lung and purge heat, cool blood, and remove toxic substance) is more effective in improving and curing skin rash, compared with the western medicine group (RR,95%CI: 1.42,1.21-1.67 and 2.43,1.23-4.81) or the blank control group(RR,95%CI:2.37,1.21-4.63 and 2.98,1.20-7.41). The side effects of CHM are all mild and tolerable. Sensitivity analysis indicates that the results of the study are stable. The asymmetry funnel plots described that publication bias of this research may exist.
    Conclusion: The limited evidence suggests that CHM exhibits clinical effectiveness and good safety on the treatment of EGFRI-induced skin rash. Large-sample RCTs are required to further determine the effectiveness of CHM.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Drugs, Chinese Herbal/therapeutic use ; ErbB Receptors/antagonists & inhibitors ; Exanthema/chemically induced ; Exanthema/drug therapy ; Humans ; Medicine, Chinese Traditional ; Neoplasms/drug therapy ; Randomized Controlled Trials as Topic
    Chemical Substances Antineoplastic Agents ; Drugs, Chinese Herbal ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2019-09-09
    Publishing country Scotland
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 1155895-7
    ISSN 1873-6963 ; 0965-2299
    ISSN (online) 1873-6963
    ISSN 0965-2299
    DOI 10.1016/j.ctim.2019.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer.

    Yang, Cai-Zhi / Hu, Lei-Hao / Huang, Zhong-Yu / Deng, Li / Guo, Wei / Liu, Shan / Xiao, Xi / Yang, Hong-Xing / Lin, Jie-Tao / Sun, Ling-Ling / Lin, Li-Zhu

    PloS one

    2021  Volume 16, Issue 12, Page(s) e0260720

    Abstract: Globally, non-small cell lung cancer (NSCLC) is the most common malignancy and its prognosis remains poor because of the lack of reliable early diagnostic biomarkers. The competitive endogenous RNA (ceRNA) network plays an important role in the ... ...

    Abstract Globally, non-small cell lung cancer (NSCLC) is the most common malignancy and its prognosis remains poor because of the lack of reliable early diagnostic biomarkers. The competitive endogenous RNA (ceRNA) network plays an important role in the tumorigenesis and prognosis of NSCLC. Tumor immune microenvironment (TIME) is valuable for predicting the response to immunotherapy and determining the prognosis of NSCLC patients. To understand the TIME-related ceRNA network, the RNA profiling datasets from the Genotype-Tissue Expression and The Cancer Genome Atlas databases were analyzed to identify the mRNAs, microRNAs, and lncRNAs associated with the differentially expressed genes. Weighted gene co-expression network analysis revealed that the brown module of mRNAs and the turquoise module of lncRNAs were the most important. Interactions among microRNAs, lncRNAs, and mRNAs were prognosticated using miRcode, miRDB, TargetScan, miRTarBase, and starBase databases. A prognostic model consisting of 13 mRNAs was established using univariate and multivariate Cox regression analyses and validated by the receiver operating characteristic (ROC) curve. The 22 immune infiltrating cell types were analyzed using the CIBERSORT algorithm, and results showed that the high-risk score of this model was related to poor prognosis and an immunosuppressive TIME. A lncRNA-miRNA-mRNA ceRNA network that included 69 differentially expressed lncRNAs (DElncRNAs) was constructed based on the five mRNAs obtained from the prognostic model. ROC survival analysis further showed that the seven DElncRNAs had a substantial prognostic value for the overall survival (OS) in NSCLC patients; the area under the curve was 0.65. In addition, the high-risk group showed drug resistance to several chemotherapeutic and targeted drugs including cisplatin, paclitaxel, docetaxel, gemcitabine, and gefitinib. The differential expression of five mRNAs and seven lncRNAs in the ceRNA network was supported by the results of the HPA database and RT-qPCR analyses. This comprehensive analysis of a ceRNA network identified a set of biomarkers for prognosis and TIME prediction in NSCLC.
    MeSH term(s) Aged ; Antineoplastic Agents/therapeutic use ; Area Under Curve ; Biomarkers, Tumor/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Regulatory Networks/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; MicroRNAs/metabolism ; Middle Aged ; Prognosis ; Proportional Hazards Models ; RNA/metabolism ; RNA, Long Noncoding/metabolism ; RNA, Messenger/metabolism ; ROC Curve ; Survival Rate
    Chemical Substances Antineoplastic Agents ; Biomarkers, Tumor ; MicroRNAs ; RNA, Long Noncoding ; RNA, Messenger ; RNA (63231-63-0)
    Language English
    Publishing date 2021-12-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0260720
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top